Kit for determining p2PSA based on latex enhanced immunoturbidimetry, preparation method and detection method

Through the p2PSA detection method based on latex enhanced immune turbidimetric method, combined with large-particle and small-particle-size latex microsphere coupled antibodies, the problems of high detection sensitivity, specificity and cost in the prior art are solved, and efficient and accurate are achieved prostate-specific antigen isomer detection.

CN119064585AActive Publication Date: 2024-12-03BEIJING QINGKE BIOTECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411384891.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-12-03
Estimated Expiration
2044-09-30

AI Technical Summary

Technical Problem

The existing prostate-specific antigen isomer detection methods have insufficient sensitivity, specificity and linearity, and are costly, which makes it difficult to meet clinical needs.

Method used

Using latex-enhanced immunoturbiditrophication method, high sensitivity, high specificity, and low-quality anti-antibody and monoclonal antibody coupled with large-particle and small-particle latex microspheres are developed by combining specific sensitizers and blockers. Cost p2PSA detection kit.

Benefits of technology

The high sensitivity, specificity and linear width of p2PSA detection are achieved, which reduces the detection cost, is suitable for a variety of instruments, and improves the accuracy and economic value of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064585A_ABST
    Figure CN119064585A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of immunodetection, in particular to a kit for determining p2PSA based on latex enhanced immunoturbidimetry, a preparation method and a detection method. The kit comprises a reaction solution and a latex antibody reagent, the reaction liquid comprises at least one of a buffer solution, inorganic salt, a sensitizer, a surfactant, a blocking agent and a preservative; the latex antibody reagent comprises a mixture of a first latex antibody reagent and a second latex antibody reagent; the first latex antibody reagent is formed by coupling a polyclonal antibody of p2PSA and large-particle-size latex microspheres; the particle size range of the large-particle-size latex microspheres is 172-405 nm; the second latex antibody reagent is formed by coupling a monoclonal antibody of p2PSA and latex microspheres with small particle sizes; the particle size range of the small-particle-size latex microspheres is 71-121 nm; the monoclonal antibody of the p2PSA comprises three strains of different monoclonal antibodies of the p2PSA; when the kit is used for determining the p2PSA, the sensitivity can be ensured, the linearity is widened, and the specificity is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of immunoassay, and in particular to a kit for measuring p2PSA based on latex-enhanced immunoturbidimetry, a preparation method and a detection method. Background Art

[0002] Prostate cancer is a common malignant tumor that endangers the health of middle-aged and elderly men. Serum prostate-specific antigen (PSA) detection combined with rectal examination is a preliminary screening method for early detection of prostate cancer. Prostate puncture biopsy can be performed to assist in diagnosis for suspected cases. However, when the patient's total PSA (tPSA) is between 4.0 and 10.0 ng / mL, which is the gray area of ​​traditional views, it is difficult to use PSA for a clear differential diagnosis. Although free PSA (fPSA) detection can be performed simultaneously and the ratio of fPSA to tPSA (f / tPSA) can be calculated for differentiation, the effect is not obvious.

[0003] Serum prostate-specific antigen isoform 2 (isoform [-2] proprostate-specific antigen, p2PSA) is an isoform of PSA precursor, which is stable and tumor-specific and has the characteristics of tissue region specificity. More and more studies have shown that compared with traditional PSA, the percentage p2PSA (%, p2PSA) and prostate health index (PHI) obtained by detection and calculation can significantly improve the diagnostic specificity of prostate cancer (PCa), reduce unnecessary prostate puncture biopsy, and show good application value in the prediction of tumor malignancy and active monitoring of low-risk and localized PCa patients.

[0004] At present, the detection method of prostate-specific antigen isomers is mainly chemiluminescence. The currently recognized prostate-specific antigen isomer test kits on the market are mainly developed based on large-scale chemiluminescence platforms. The clinical detection of serum prostate-specific antigen isomers (p2PSA) is mainly based on the prostate-specific antigen isomer determination kit (chemiluminescence method) produced by Beckman Coulter Company abroad. The chemiluminescence method is closed, and the price of imported reagents is very expensive. It needs to be equipped with corresponding instruments, which brings a great economic burden to patients. Moreover, for a single test, the chemiluminescence method usually takes about 1 hour to report the results, and the sensitivity, specificity and linearity are difficult to be satisfactory. Therefore, the clinic needs a detection method with high sensitivity, high specificity, good linearity, simple operation, low cost, and suitable for a variety of instruments. Summary of the invention

[0005] Therefore, the technical problem to be solved by the present invention is to provide a kit, preparation method and detection method for determining p2PSA based on latex-enhanced immunoturbidimetry with high sensitivity, high specificity, good linearity, simple operation, low cost and applicability to a variety of instruments.

[0006] To this end, the present invention provides the following technical solutions:

[0007] The embodiments disclosed in the present invention relate to a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, the kit comprising: a latex antibody reagent;

[0008] The latex antibody reagent includes a mixture of a first latex antibody reagent and a second latex antibody reagent; the first latex antibody reagent is formed by coupling a polyclonal antibody of p2PSA with large-particle latex microspheres; the particle size range of the large-particle latex microspheres is 172 to 405 nm; the second latex antibody reagent is formed by coupling a monoclonal antibody of p2PSA with small-particle latex microspheres; the particle size range of the small-particle latex microspheres is 71 to 121 nm; the monoclonal antibody of p2PSA includes 3 different monoclonal antibodies of p2PSA.

[0009] As a preferred embodiment, the polyclonal antibody against p2PSA is p2PSA-pAb;

[0010] And / or, the monoclonal antibody against p2PSA includes p2PSA-1, p2PSA-2 and p2PSA-3 monoclonal antibodies; the p2PSA-1 monoclonal antibody is p2PSA-mAb-1; the p2PSA-2 monoclonal antibody is p2PSA-mAb-2; and the p2PSA-3 monoclonal antibody is p2PSA-mAb-3.

[0011] As a preferred embodiment, the particle size of the large-size latex microspheres is 405nm, 218nm, 192nm or 172nm, preferably 405nm;

[0012] And / or, the particle size of the small-size latex microspheres is 71 nm, 89 nm, 100 nm, 108 nm or 121 nm, preferably 71 nm;

[0013] And / or, the volume ratio of the polyclonal antibody of p2PSA to the large-particle latex microspheres is 2 to 5:1, preferably 2:1; the concentration of the polyclonal antibody of p2PSA is 2 mg / L to 20 mg / L; the concentration of the large-particle latex microspheres is 0.5% w / v to 1% w / v;

[0014] And / or, the volume ratio of the p2PSA monoclonal antibody to the small-particle latex microspheres is 2 to 5:1, preferably 2:1; the concentration of the p2PSA monoclonal antibody is 2 mg / L to 20 mg / L; the concentration of the small-particle latex microspheres is 0.5% w / v to 1% w / v;

[0015] and / or, the mass ratio of p2PSA-1, p2PSA-2 and p2PSA-3 monoclonal antibodies is 1:1:9 to 9:1:1; preferably 1:1:1;

[0016] And / or, the volume ratio of the first latex antibody reagent to the second latex antibody reagent is 1:3 to 3:1, preferably 1:2 to 2:1; preferably, 1:1;

[0017] And / or, the concentration of the polyclonal antibody of p2PSA and the large-size latex microsphere conjugate in the first latex antibody reagent is 0.1-0.5w / v%, preferably 0.3w / v%;

[0018] And / or, the concentration of the conjugate of p2PSA monoclonal antibody and small-particle latex microspheres in the second latex antibody reagent is 0.05-0.3w / v%, preferably 0.1w / v%.

[0019] In some embodiments, a reaction solution is further included; the reaction solution includes at least one of a buffer, an inorganic salt, a sensitizer, a surfactant, a blocking agent, and a preservative;

[0020] The buffer comprises any one of N(2-acetylamino)-2-iminodiacetic acid buffer, piperidine-N,N-bis(2-ethanesulfonic acid) buffer, 3-[N,N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer;

[0021] And / or, the inorganic salt includes at least one of sodium molybdate, ammonium molybdate, sodium bisulfate or ammonium bisulfate;

[0022] And / or, the sensitizer includes at least one of Biolipidure 103, Biolipidure 405, and PEG 6000; preferably Biolipidure 103 and / or Biolipidure 405;

[0023] And / or, the preservative is at least one of sodium azide, gentamicin, and isothiazolinone;

[0024] And / or, the surfactant is at least one of polyoxyethylene fatty alcohol ether, fatty acid glyceride, sucrose fatty acid ester, fatty acid sorbitan, and polysorbate;

[0025] And / or, the blocking agent is at least one of THBR-1, THBR-2, and A1101; preferably, THBR-1, THBR-2, and A1101, with a volume ratio of 0.5-1.5:0.5-1.5:0.5-1.5, more preferably 1:1:1;

[0026] Optionally, the reaction solution includes: 13-18.2 g / L buffer, 8.5-20 g / L inorganic salt, 20-35 g / L sensitizer, 0.1-0.2 v / v% surfactant, 0.002-0.006 v / v% blocker, 0.5-1.5 g / L preservative; pH is 7.2±0.05-8.2±0.05.

[0027] In some embodiments, a calibrator is further included; the calibrator contains human p2PSA antigen;

[0028] Optionally, the calibrator comprises 13 to 18.2 g / L of buffer, 0.5 to 1 g / L of protective agent, and 13 to 18.2 g / L of preservative;

[0029] Optionally, the buffer comprises any one of a phosphate buffer, an N(2-acetylamino)-2-iminodiacetic acid buffer, a piperidine-N,N-bis(2-ethanesulfonic acid) buffer, a 3-[N,N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and a 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer;

[0030] Optionally, the protective agent is at least one of bovine serum albumin, casein, gelatin or NaCl;

[0031] Optionally, the preservative is at least one of sodium azide, gentamicin, and isothiazolinone.

[0032] The embodiment disclosed in the present invention relates to a method for preparing a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, comprising the following steps:

[0033] The large-size latex microspheres and the small-size latex microspheres are activated by EDC and N-hydroxysulfosuccinimide (sulfo-NHS) respectively for later use;

[0034] The activated large-size latex microspheres are coupled with the polyclonal antibody of p2PSA, blocked, centrifuged to remove the supernatant, and resuspended to obtain the first latex antibody reagent;

[0035] The activated small-size latex microspheres are coupled with the p2PSA monoclonal antibody, blocked, centrifuged to remove the supernatant, and resuspended to obtain a second latex antibody reagent;

[0036] The first latex antibody reagent and the second latex antibody reagent are mixed in proportion to obtain a latex antibody reagent.

[0037] In some embodiments, prior to coupling, the large-size latex microspheres are washed, centrifuged, and redissolved;

[0038] and / or, before coupling, the small-size latex microspheres are washed, centrifuged, and redissolved;

[0039] And / or, the volume ratio of carbodiimide and N-hydroxysulfosuccinimide added is 3-5:6-10, preferably 1:2, the concentration of carbodiimide is 10-30 mg / ml, and the concentration of sulfosuccinimide is 20-30 mg / mL;

[0040] And / or, the blocking solution used in the blocking step includes at least one of DB1130, CE510, and CE210;

[0041] And / or, the resuspension step uses a preservation solution for resuspension, and the preservation solution includes a buffer, a stabilizer, a surfactant and a preservative; wherein the buffer includes any one of piperidine-N, N-bis(2-ethanesulfonic acid) buffer, 3-[N, N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer; the stabilizer includes at least one of gelatin or casein; the surfactant is at least one of polyoxyethylene fatty alcohol ether, fatty acid glyceride, sucrose fatty acid ester, fatty acid sorbitan, and polysorbate; the preservative is at least one of sodium azide, gentamicin, and isothiazolinones.

[0042] The embodiment disclosed in the present invention relates to the use of a kit for determining p2PSA based on latex-enhanced immunoturbidimetry in the preparation of a product for determining p2PSA.

[0043] The embodiment disclosed in the present invention relates to a method for determining p2PSA based on latex-enhanced immunoturbidimetry, which uses a sample to be tested and a kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to any one of claims 1 to 5 to perform an immune reaction, and performs turbidity detection on the obtained reaction product.

[0044] In some embodiments, the method comprises: mixing the sample to be tested and the calibrator with the reaction solution respectively, incubating, then adding the latex antibody reagent, and then measuring the absorbance of the sample to be tested and the calibrator respectively; drawing a standard curve according to the content of the calibrator and the measured absorbance, and calculating the content of p2PSA in the sample to be tested according to the standard curve;

[0045] Optionally, the volume ratio of the sample to be tested, the reaction solution and the latex antibody reagent is 10-20:90-270:30-90, preferably 15:180:60.

[0046] The technical solution of the present invention has the following advantages:

[0047] 1. The present invention provides a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, the kit comprising: a reaction solution and a latex antibody reagent; the reaction solution comprises at least one of a buffer solution, an inorganic salt, a sensitizer, a surfactant, a blocking agent, and a preservative; the latex antibody reagent comprises a mixture of a first latex antibody reagent and a second latex antibody reagent; the first latex antibody reagent is formed by coupling a polyclonal antibody of p2PSA with large-particle latex microspheres; the particle size range of the large-particle latex microspheres is 172 to 405 nm; the second latex antibody reagent is formed by coupling a monoclonal antibody of p2PSA with small-particle latex microspheres; the particle size range of the small-particle latex microspheres is 71 to 121 nm; the monoclonal antibody of p2PSA comprises 3 different monoclonal antibodies of p2PSA; the present invention has found that the latex-enhanced immunoturbidimetry method for determining p2PSA SA, latex microspheres of different particle sizes will affect the sensitivity, specificity and linearity of p2PSA determination. It is found that the larger the particle size, the higher the sensitivity; the smaller the particle size, the wider the linearity. The latex antibody reagent prepared by latex microspheres of large and small particle sizes selected by the present invention can ensure sensitivity, while broadening linearity and enhancing specificity. The p2PSA monoclonal antibody includes three different monoclonal antibodies p2PSA coated with small-particle microspheres at the same time. The specificity of the monoclonal antibody is relatively high. A single monoclonal antibody only recognizes a specific antigen epitope. This ultra-high specificity will reduce the sensitivity. Therefore, the present invention uses three different monoclonal antibodies to simultaneously coat small-particle microspheres. Compared with traditional monoclonal antibodies paired in pairs, the specificity will be higher and the binding sites for the antigen are more. In summary, the above-mentioned kit can detect p2PSA with high sensitivity, high specificity and wide linearity.

[0048] 2. The present invention provides a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, wherein the polyclonal antibody of p2PSA is p2PSA-pAb; and / or the monoclonal antibody of p2PSA includes p2PSA-1, p2PSA-2 and p2PSA-3 monoclonal antibodies; the p2PSA-1 monoclonal antibody is p2PSA-mAb-1; the p2PSA-2 monoclonal antibody is p2PSA-mAb-2; the p2PSA-3 monoclonal antibody is p2PSA-mAb-3 Ab-3; The present invention has found that for the latex enhanced immunoturbidimetry method to determine p2PSA, large-particle microspheres are used to couple with p2PSA polyclonal antibodies with stronger affinity, and small-particle microspheres are used to couple with p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies with stronger specificity. Since the three different monoclonal antibodies p2PSA-1, p2PSA-2, and p2PSA-3 are coated with small-particle microspheres at the same time, this method is different from the traditional monoclonal antibody method. The advantage of the labeled latex enhanced immunoturbidimetry is that the specificity of the monoclonal antibody is high. A single monoclonal antibody only recognizes a specific antigen epitope. This ultra-high specificity will reduce the sensitivity. Therefore, the present invention adopts a detection method in which three different monoclonal antibodies are simultaneously coated with small-particle microspheres. Compared with the traditional monoclonal antibody pairing, this method has higher specificity and targets more antigen binding sites. There is no competition for binding positions between antibodies, thereby further improving the detection sensitivity. Therefore, the present invention uses a polyclonal antibody with a strong affinity selected by coupling with large-particle microspheres to ensure the sensitivity of the reagent, and uses three monoclonal antibodies with strong specificity selected by coupling with small-particle microspheres to ensure the linearity and specificity of the reagent. The two are mixed to obtain a latex antibody reagent (R2), which perfectly avoids the problems of low sensitivity of monoclonal antibodies and poor specificity of polyclonal antibodies. The combination of the two not only ensures sensitivity, but also broadens the linearity of the reagent and has a strong specificity.

[0049] 3. The present invention provides a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, in which the sensitizer used in R1 is a Biolipidure series product, which is different from the traditional polyethylene glycol turbidifier. The Biolipidure series sensitizers have better effects and stronger specificity. Principle of action: Biolipidure-103 has strong hydrophilicity and occupies a certain physical space in the solution, which indirectly increases the concentration of antigens and antibodies; in addition, it forms a loose and porous form in the solution, giving the antigens and antibodies a smaller and more efficient reaction space. The functional group of Biolipidure-405 is an anion, which has strong dispersibility, can greatly improve the dispersibility of antigens and antibodies, and improve the uniformity of the reaction; the Biolipidure-405 polymer structure will also occupy a certain physical space in the solution, which indirectly increases the concentration of antigens and antibodies and improves reactivity.

[0050] 4. A kit for determining p2PSA based on latex-enhanced immunoturbidimetry provided by the present invention, wherein the blocker is at least one of THBR-1, THBR-2, and A1101; preferably, THBR-1, THBR-2, and A1101, with a volume ratio of 1:1:1; three different blockers are added and used simultaneously in R1 of the present invention, and the anti-interference effect of the present invention is better than that of the traditional method of adding only one blocker. Traditional blockers can reduce the interference of endogenous substances to a certain extent, but not all immune interference can be removed. The present invention uses three different blockers in combination to eliminate false positive results caused by various interferences, which is efficient and convenient. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0052] Figure 1 is the standard curve of the calibrator in Example 18 of the present invention;

[0053] Figure 2 is the correlation result between the sample measurement result and the theoretical result in Example 18 of the present invention;

[0054] Figure 3 The results of 1) the influence of microspheres with different particle sizes on the signal value in the experimental examples of the present invention;

[0055] Figure 4 The results of the influence of mixing different monoclonal antibodies on the signal value in the experimental example 2) of the present invention;

[0056] Figure 5 The results of the influence of the mixing ratio of microspheres with large and small particle sizes on the signal value in the experimental example 3) of the present invention;

[0057] Figure 6 The results of the effects of different turbidity enhancers on the signal value in the experimental example 4) of the present invention;

[0058] Figure 7 This is the comparison result of the detection result of the kit in Example 1 and the measurement result of the Beckman Coulter kit in the accuracy experiment 8) in the experimental example of the present invention. DETAILED DESCRIPTION

[0059] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0060] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0061] The present invention has found that in the application of latex enhanced immunoturbidimetry, the use of polyclonal antibodies for labeling can improve the sensitivity to a certain extent, but the specificity of polyclonal antibodies is poor, and the problem of decreased accuracy of the test results will occur. The use of monoclonal antibodies to label latex can improve the specificity of the reagent, but the sensitivity will be affected. In response to the above problems, the present invention combines the characteristics of antigens, antibodies and latex microspheres, and the selection of antigens and antibodies is mainly to compare their isoelectric points, specificity and affinity. The higher the affinity of the raw material, the higher the sensitivity, but too high may affect the linearity; the better the specificity of the raw material, the better the clinical relevance. The selection of latex microspheres is mainly to compare the particle size: the larger the particle size, the higher the sensitivity; the smaller the particle size, the wider the linearity. Large-diameter microspheres were used to couple p2PSA polyclonal antibodies with strong affinity, and small-diameter microspheres were used to couple p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies with strong specificity. The two were mixed in a 1:1 ratio to prepare the latex antibody reagent (R2), which perfectly avoided the problems of low sensitivity of monoclonal antibodies and poor specificity of polyclonal antibodies. The combination of the two not only ensured the sensitivity, but also broadened the linearity of the reagent and made it more specific. At the same time, adding a blocking agent to the reagent greatly improved the anti-interference ability of the reagent.

[0062] Therefore, the present invention discloses a kit for determining p2PSA based on latex enhanced immunoturbidimetry and a preparation method thereof, the main steps of which are: screening out p2PSA-1, p2PSA-2, p2PSA-3 monoclonal antibodies with strong specificity and p2PSA polyclonal antibodies with high affinity, coupling polyclonal antibodies with large-diameter latex microspheres, coupling monoclonal antibodies with small-diameter microspheres, and then mixing the two in a 1:1 ratio to form a latex antibody reagent, and then preparing an R1 reagent, and finally combining the latex antibody reagent (R2 reagent), the R1 reagent and a calibrator to form a kit, which can simultaneously improve the sensitivity, specificity and linearity of the latex enhanced immunoturbidimetry for determining p2PSA, so that the sensitivity of the kit is higher, the linear range is wider, and the accuracy is higher. It has extremely high economic value and broad market application prospects. The kit prepared by the preparation method of the present invention has a minimum detection limit of 1.02 pg / mL; the reagent has good precision, and the CV can be controlled within 1%, which is much lower than the industry standard requirement of 10%; the linear range can be as high as 8000 pg / mL, which is much higher than the linearity of 5000 pg / mL of conventional kits, and the correlation coefficient R 2 Greater than 0.99; the reagent has strong anti-interference ability, bilirubin ≤40mg / dL, fat emulsion ≤0.5%, RF ≤400IU / mL, hemoglobin ≤500mg / dL, high clinical comparison accuracy, and the correlation coefficient R2 is greater than the industry standard requirement of 0.95.

[0063] In the following examples, Biolipidure 103 and Biolipidure 405 were purchased from Beijing Boerma Biotechnology Co., Ltd.;

[0064] Blockers THBR-1, THBR-2, and A1101 were purchased from Beijing Boerma Biotechnology Co., Ltd.;

[0065] Blocking solutions DB1130, CE510, and CE210 were purchased from Beijing Boerma Biotechnology Co., Ltd.;

[0066] The polyclonal antibody against p2PSA involved in the following embodiments is p2PSA-pAb, the monoclonal antibody against p2PSA-1 is p2PSA-mAb-1, the monoclonal antibody against p2PSA-2 is p2PSA-mAb-2, and the monoclonal antibody against p2PSA-3 is p2PSA-mAb-3. All of the above antibodies were purchased from Wuhan Aokebot Biotechnology Co., Ltd.

[0067] Example 1

[0068] This embodiment provides a kit for determining p2PSA based on latex-enhanced immunoturbidimetry, including: p2PSA reagent R1 (reaction solution) and p2PSA reagent R2 (latex antibody reagent).

[0069] 1. Preparation of p2PSA reagent R1 (reaction solution):

[0070] Accurately weigh the chemical substances according to the ratio in Table 1 below, place them in a beaker filled with 0.8 L of pure water, stir and mix, adjust the pH value to 7.20±0.05 with 3 mol / L dilute hydrochloric acid, transfer the solution to a 1 L volumetric flask, filter the solution with a 0.22 um filter membrane, store the prepared solution in a glass container, label it, and store it at 2-8°C.

[0071]

[0072] 2. Preparation of p2PSA reagent R2, i.e. latex antibody reagent:

[0073] 1. Washing: Take 100ul of microspheres (JSR 405nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 20min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR71nm) (5% w / v) in the same way, add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0074] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 405nm (volume 1000uL) and 71nm (volume 1000uL) microspheres dispersed in step 1 respectively for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL). First add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50Mm boric acid-borax pH8.0, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0075] 3. Coupling: Take p2PSA polyclonal antibody, take a mixture of p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies (p2PSA-1, p2PSA-2, and p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0 to make a final volume of 2000uL, and obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively, add 405nm activated microspheres (concentration of 1% w / v) to the polyclonal antibody dilution, and add 71nm activated microspheres (concentration of 0.5% w / v) to the monoclonal antibody mixture dilution, place in a shaker for coupling, and couple at 30°C for 4h.

[0076] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 30 minutes and remove the supernatant. The blocking solution is DB1130.

[0077] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0078] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 5 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 405 nm microsphere latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 71 nm microsphere latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio, and stored at 2-8 ° C for use.

[0079] Comparative Example 1

[0080] The difference between this embodiment and embodiment 1 is: 2. Preparation of p2PSA reagent R2, i.e., latex antibody reagent:

[0081] 1. Washing: Take 100ul of microspheres (JSR 405nm) (10% w / v), add 900uL of 2-(N-morpholine)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) to wash, centrifuge (20000G centrifugal force, 20min), remove the supernatant and re-dissolve with 1000uL of MES, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0082] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 405nm microspheres (volume 1000uL) dispersed in step 1 for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL), first add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50Mm boric acid-borax pH8.0, and disperse by ultrasound for 5min using a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0083] 3. Coupling: Take the p2PSA polyclonal antibody and monoclonal antibody mixture (p2PSA-1, p2PSA-2, p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0 to make the final volume 2000uL, and obtain the polyclonal antibody dilution (concentration is 5mg / ml), the monoclonal antibody mixture dilution (concentration is 10mg / ml), and then add the activated 405nm microspheres (1000uL, concentration is 1% w / v), respectively, and place in a shaker for coupling at 30℃ for 4h.

[0084] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 30 minutes and remove the supernatant. The blocking solution is DB1130.

[0085] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0086] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 5 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 405 nm microspheres coupled to polyclonal antibody latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 405 nm microspheres coupled to monoclonal antibody mixture latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) are mixed in a 1:1 volume ratio and stored at 2-8 ° C for later use.

[0087] Comparative Example 2

[0088] The difference between this embodiment and embodiment 1 is that, 2. Preparation of p2PSA reagent R2, i.e., latex antibody reagent:

[0089] 1. Washing: Take 100ul of microspheres (JSR71nm) (5% w / v), add 900uL of 2-(N-morpholine)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval for 0.5S.

[0090] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 71nm microspheres (volume 1000uL) dispersed in step 1 for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL), first add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50mM boric acid-borax pH8.0, and disperse by ultrasound for 5min using a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0091] 3. Coupling: Take the p2PSA polyclonal antibody and monoclonal antibody mixture (p2PSA-1, p2PSA-2, p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50Mm boric acid-borax pH8.0 to make the final volume 2000uL, and obtain the polyclonal antibody dilution (concentration of 5mg / ml) and the monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add the activated 71nm microspheres (1000uL, concentration 0.5% w / v) respectively, place in a shaker for coupling, and couple at 30℃ for 4h.

[0092] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 40 minutes and remove the supernatant. The blocking solution is DB1130.

[0093] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0094] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 5 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 71 nm microspheres coupled to polyclonal antibodies in latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 71 nm microspheres coupled to monoclonal antibodies in latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio and stored at 2-8 °C for later use.

[0095] Comparative Example 3

[0096] The difference between this embodiment and embodiment 1 is that, 2. Preparation of p2PSA reagent R2, i.e., latex antibody reagent:

[0097] 1. Washing: Take 100ul of microspheres (JSR272nm) (10% w / v), add 900uL of 2-(N-morpholine)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval for 0.5S.

[0098] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 272nm microspheres (volume 1000uL) dispersed in step 1 for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL), first add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50mM boric acid-borax pH8.0, and disperse by ultrasound for 5min using a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0099] 3. Coupling: Take the p2PSA polyclonal antibody and monoclonal antibody mixture (p2PSA-1, p2PSA-2, p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50Mm boric acid-borax pH8.0 to make the final volume 2000uL, and obtain the polyclonal antibody dilution (concentration of 5mg / ml) and monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add the activated 272nm microspheres (1000uL) respectively, place in a shaker for coupling, and couple at 30℃ for 4h.

[0100] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 40 minutes and remove the supernatant. The blocking solution is DB1130.

[0101] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0102] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 5 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 272 nm microspheres coupled to polyclonal antibodies (the first latex antibody reagent) (concentration of 0.3 w / v%) and the 272 nm microspheres coupled to monoclonal antibodies (the second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio and stored at 2-8 °C for later use.

[0103] Comparative Example 4

[0104] The difference between this embodiment and embodiment 1 is that, 2. Preparation of p2PSA reagent R2, i.e., latex antibody reagent:

[0105] 1. Washing: Take 100ul of microspheres (JSR83nm) (5% w / v), add 900uL of 2-(N-morpholine)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval for 0.5S.

[0106] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 83nm microspheres (volume 1000uL) dispersed in step 1 for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL), first add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50mM boric acid-borax pH8.0, and disperse by ultrasound for 5min using a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0107] 3. Coupling: Take the p2PSA polyclonal antibody and monoclonal antibody mixture (p2PSA-1, p2PSA-2, p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50Mm boric acid-borax pH8.0, and make the final volume 2000uL to obtain polyclonal antibody dilution (concentration of 5mg / ml) and monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated 83nm microspheres (1000uL) respectively, place in a shaker for coupling, and couple at 30℃ for 4h.

[0108] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 40 minutes and remove the supernatant. The blocking solution is DB1130.

[0109] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0110] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 5 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 83 nm microspheres coupled to polyclonal antibodies in latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 83 nm microspheres coupled to monoclonal antibodies in latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio and stored at 2-8 °C for later use.

[0111] Comparative Example 5

[0112] The difference between this embodiment and embodiment 1 is that, 2. Preparation of p2PSA reagent R2, i.e., latex antibody reagent:

[0113] 1. Washing: Take 100ul of microspheres (JSR 405nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 20min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR71nm) (5% w / v) and add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0114] 2. Activation: Add EDC and sulfo-NHS (ratio of 4uL:8uL) to the 405nm and 71nm microspheres dispersed in step 1 for activation (EDC concentration is 20mg / ml, sulfo-NHS concentration is 30mg / mL), first add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, remove the supernatant, re-dissolve to 1000uL with 50Mm boric acid-borax pH8.0, and disperse by ultrasound for 5min with a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0115] 3. Coupling: Take a mixture of p2PSA polyclonal antibody and monoclonal antibody (p2PSA-1 and p2PSA-2 are mixed in a mass ratio of 1:1), add 50mM boric acid-borax pH8.0 to make the final volume 2000uL, and obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively, add 405nm activated microspheres (concentration of 1% w / v) to the polyclonal antibody dilution, and add 71nm activated microspheres (concentration of 0.5% w / v) to the monoclonal antibody mixture dilution, place in a shaker for coupling, and couple at 30°C for 4h.

[0116] 4. Blocking: Add 230ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 30 minutes and remove the supernatant. The blocking solution is DB1130.

[0117] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0118] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.5% TWEEN-20 + 0.1% sodium azide, pH 7.20) to the precipitate for re-dissolution, and use a cell disruptor to ultrasonically disperse for 5 min, ultrasonically for 0.5 s, with an interval of 0.5 s. The re-dissolved 405 nm microsphere latex reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 71 nm microsphere latex reagent (second latex antibody reagent) (concentration of 0.1 w / v%) are mixed in a 1:1 volume ratio and stored at 2-8°C for later use.

[0119] Comparative Example 6

[0120] The difference between this example and comparative example 5 is that the p2PSA-2 antibody is replaced by the p2PSA-3 antibody.

[0121] Comparative Example 7

[0122] The difference between this example and comparative example 5 is that the p2PSA-1 antibody is replaced by the p2PSA-3 antibody.

[0123] Example 2

[0124] The difference between this embodiment and embodiment 1 is that the reconstituted 405 nm microsphere latex reagent (first latex antibody reagent) and the 71 nm microsphere latex reagent (second latex antibody reagent) are mixed in a volume ratio of 2:1.

[0125] Example 3

[0126] The difference between this embodiment and embodiment 1 is that the reconstituted 405 nm microsphere latex reagent (first latex antibody reagent) and the 71 nm microsphere latex reagent (second latex antibody reagent) are mixed in a volume ratio of 1:2.

[0127] Example 4

[0128] The difference between this embodiment and embodiment 1 is that the reconstituted 405 nm microsphere latex reagent (first latex antibody reagent) and the 71 nm microsphere latex reagent (second latex antibody reagent) are mixed in a volume ratio of 3:1.

[0129] Example 5

[0130] The difference between this embodiment and embodiment 1 is that the reconstituted 405 nm microsphere latex reagent (first latex antibody reagent) and the 71 nm microsphere latex reagent (second latex antibody reagent) are mixed in a volume ratio of 1:3.

[0131] Example 6

[0132] The difference between this embodiment and embodiment 1 is that the mass of Biolipidure 103 in the reaction solution formula of Table 1 is replaced by PEG 6000.

[0133] Example 7

[0134] The difference between this embodiment and embodiment 1 is that the mass of Biolipidure 103 in the reaction solution formula of Table 1 is replaced by Biolipidure 405.

[0135] Example 8

[0136] 1. Preparation of p2PSA reagent R1 (reaction solution):

[0137] Accurately weigh the chemical substances according to the ratio in the following list, place them in a beaker filled with 0.8L pure water, stir and mix, adjust the pH value to 7.50±0.05 with 3mol / L dilute hydrochloric acid, transfer the solution to a 1L volumetric flask, filter the solution with a 0.22um filter membrane, store the prepared solution in a glass container, label it, and store it at 2-8℃.

[0138]

[0139] 2. Preparation of p2PSA reagent R2, i.e. latex antibody reagent:

[0140] 1. Washing: Take 100ul of microspheres (JSR 218nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 30min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 8min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR89nm) (5% w / v) in the same way, add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 35min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0141] 2. Activation: Add EDC and sulfo-NHS (ratio of 5uL:10uL) to the 218nm (volume 1000uL) and 89nm (volume 1000uL) microspheres dispersed in step 1 for activation (EDC concentration is 30mg / ml, sulfo-NHS concentration is 20mg / mL). First add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 30min, re-dissolve to 1000uL with 50Mm boric acid-borax pH8.0, and disperse by ultrasound with a cell disruptor for 8min, ultrasound for 0.5S, and interval of 0.5S.

[0142] 3. Coupling: Take p2PSA polyclonal antibody, take a mixture of p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies (p2PSA-1, p2PSA-2, and p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0, and make the final volume 2000uL to obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively, add 218nm activated microspheres to the polyclonal antibody dilution, and add 89nm activated microspheres to the monoclonal antibody mixture dilution, place in a shaker for coupling, and couple at 30℃ for 4h.

[0143] 4. Blocking: Add 280ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 30 minutes and remove the supernatant. The blocking solution is DB1130.

[0144] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0145] 6. Resuspend: Add 2.5 mL of latex diluent (50 mm PIPES + 0.5% BSA + 0.1% TWEEN-20 + 0.1% sodium azide, pH 7.5) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 8 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 218 nm microsphere latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 89 nm microsphere latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio and stored at 2-8 °C for later use.

[0146] Example 9

[0147] 1. Preparation of p2PSA reagent R1 (reaction solution):

[0148] Accurately weigh the chemical substances according to the ratio in the following list, place them in a beaker filled with 0.8L pure water, stir and mix, adjust the pH value to 7.80±0.05 with 3mol / L dilute hydrochloric acid, transfer the solution to a 1L volumetric flask, filter the solution with a 0.22um filter membrane, store the prepared solution in a glass container, label it, and store it at 2-8℃.

[0149]

[0150] 2. Preparation of p2PSA reagent R2, i.e. latex antibody reagent:

[0151] 1. Washing: Take 100ul of microspheres (JSR 218nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 40min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 10min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR100nm) (5% w / v) in the same way, add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 35min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0152] 2. Activation: Add EDC and sulfo-NHS (ratio of 3uL:6uL) to the 218nm (volume 1000uL) and 100nm (volume 1000uL) microspheres dispersed in step 1 for activation (EDC concentration is 10mg / ml, sulfo-NHS concentration is 25mg / mL). First add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 40min, remove the supernatant, re-dissolve to 1000uL with 50mM boric acid-borax pH8.0, and disperse by ultrasonication for 8min with a cell disruptor, ultrasonication for 0.5S, and interval of 0.5S.

[0153] 3. Coupling: Take p2PSA polyclonal antibody, take a mixture of p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies (p2PSA-1, p2PSA-2, and p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0, and make the final volume 2000uL to obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively. 218nm activated microspheres should be added to the polyclonal antibody dilution, and 100nm activated microspheres should be added to the monoclonal antibody mixture dilution. Place them in a shaker for coupling at 30℃ for 3.5h.

[0154] 4. Blocking: Add 310ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 40 minutes and remove the supernatant. The blocking solution is DB1130.

[0155] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0156] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 0.5% BSA + 0.2% TWEEN-20 + 0.1% sodium azide, pH 7.8) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 10 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 218 nm microsphere latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 100 nm microsphere latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) were mixed in a 1:1 volume ratio, and stored at 2-8°C for use.

[0157] Example 10

[0158] 1. Preparation of p2PSA reagent R1 (reaction solution):

[0159] Accurately weigh the chemical substances according to the ratio in the following list, place them in a beaker filled with 0.8L pure water, stir and mix, adjust the pH value to 8.00±0.05 with 3mol / L dilute hydrochloric acid, transfer the solution to a 1L volumetric flask, filter the solution with a 0.22um filter membrane, store the prepared solution in a glass container, label it, and store it at 2-8℃.

[0160]

[0161]

[0162] 2. Preparation of p2PSA reagent R2, i.e. latex antibody reagent:

[0163] 1. Washing: Take 100ul of microspheres (JSR 192nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 50min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 12min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR108nm) (5% w / v) in the same way, add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 35min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0164] 2. Activation: Add EDC and sulfo-NHS (ratio of 3uL:6uL) to the 192nm and 108nm microspheres dispersed in step 1 for activation (EDC concentration is 25mg / ml, sulfo-NHS concentration is 20mg / mL). First add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 50min, remove the supernatant, re-dissolve to 1000uL with 50Mm boric acid-borax pH8.0, and disperse by ultrasound for 10min with a cell disruptor, ultrasound for 0.5S, and interval of 0.5S.

[0165] 3. Coupling: Take p2PSA polyclonal antibody, take a mixture of p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies (p2PSA-1, p2PSA-2, and p2PSA-3 are in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0, and make the final volume 2000uL to obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively, add 192nm activated microspheres to the polyclonal antibody dilution, and add 108nm activated microspheres to the monoclonal antibody mixture dilution, place in a shaker for coupling, and couple at 30℃ for 3h.

[0166] 4. Blocking: Add 310ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 50 minutes and remove the supernatant. The blocking solution is DB1130.

[0167] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0168] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.2% TWEEN-20 + 0.1% Proclin300, pH 8.0) to the precipitate for re-dissolution, use a cell disruptor for ultrasonic dispersion for 10 min, ultrasonic for 0.5 s, and interval for 0.5 s. Mix the re-dissolved 192 nm microsphere latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 108 nm microsphere latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) in a 1:1 volume ratio, and store at 2-8°C for use.

[0169] Embodiment 11

[0170] 1. Preparation of p2PSA reagent R1 (reaction solution):

[0171] Accurately weigh the chemical substances according to the ratio in the following list, place them in a beaker filled with 0.8L pure water, stir and mix, adjust the pH value to 8.20±0.05 with 3mol / L dilute hydrochloric acid, transfer the solution to a 1L volumetric flask, filter the solution with a 0.22um filter membrane, store the prepared solution in a glass container, label it, and store it at 2-8℃.

[0172]

[0173] 2. Preparation of p2PSA reagent R2, i.e. latex antibody reagent:

[0174] 1. Washing: Take 100ul of microspheres (JSR 172nm) (10% w / v), add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (20000G centrifugal force, 55min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 15min, ultrasonically for 0.5S, and at intervals of 0.5S. Take 100ul of microspheres (JSR121nm) (5% w / v) in the same way, add 900uL of 2-(N-morpholino)-ethanesulfonic acid (also known as MES: 20mM pH 5.5) for washing, centrifuge (25000G centrifugal force, 35min), remove the supernatant and re-dissolve with 1000uL of MES, and ultrasonically disperse with a cell disruptor for 5min, ultrasonically for 0.5S, and at intervals of 0.5S.

[0175] 2. Activation: Add EDC and sulfo-NHS (ratio of 3uL:6uL) to the 172nm (volume 1000uL) and 121nm (volume 1000uL) microspheres dispersed in step 1 for activation (EDC concentration is 30mg / ml, sulfo-NHS concentration is 25mg / mL). First add EDC, then add sulfo-NHS, activate at 30℃ for 20min, centrifuge at 20000G for 55min, remove the supernatant, re-dissolve to 1000uL with 50mM boric acid-borax pH8.0, and disperse by ultrasonication for 15min with a cell disruptor, ultrasonication for 0.5S, and interval of 0.5S.

[0176] 3. Coupling: Take p2PSA polyclonal antibody, take a mixture of p2PSA-1, p2PSA-2, and p2PSA-3 monoclonal antibodies (p2PSA-1, p2PSA-2, and p2PSA-3 are mixed in a mass ratio of 1:1:1), add 50mM boric acid-borax pH8.0, and make the final volume 2000uL to obtain polyclonal antibody dilution (concentration of 5mg / ml), monoclonal antibody mixture dilution (concentration of 10mg / ml), and then add activated microspheres (1000uL) respectively, add 172nm activated microspheres to the polyclonal antibody dilution, and add 121nm activated microspheres to the monoclonal antibody mixture dilution, place in a shaker for coupling, and couple at 30℃ for 2.5h.

[0177] 4. Blocking: Add 310ul of blocking solution and block on a shaker for 1 hour. Centrifuge at 20000G for 50 minutes and remove the supernatant. The blocking solution is DB1130.

[0178] 5. Cleaning: Wash the precipitate twice with cleaning solution and centrifuge to remove the supernatant.

[0179] 6. Resuspend: Add 2.5 mL of latex diluent (50 mM PIPES + 1% BSA + 0.2% TWEEN-20 + 0.1% Proclin300, pH 8.5) to the precipitate for re-dissolution, and use a cell disruptor for ultrasonic dispersion for 15 min, ultrasonic for 0.5 s, with an interval of 0.5 s. The re-dissolved 172 nm microsphere latex antibody reagent (first latex antibody reagent) (concentration of 0.3 w / v%) and 121 nm microsphere latex antibody reagent (second latex antibody reagent) (concentration of 0.1 w / v%) are mixed in a 1:1 volume ratio and stored at 2-8 °C for later use.

[0180] Example 12

[0181] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is only THBR-1, 60 μl.

[0182] Example 13

[0183] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is only 60 μl of THBR-2.

[0184] Embodiment 14

[0185] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is only 60 μl of A1101.

[0186] Embodiment 15

[0187] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is replaced by 30 μl of THBR-1 and 30 μl of THBR-2.

[0188] Example 16

[0189] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is replaced by 30 μl of THBR-1 and 30 μl of A1101.

[0190] Embodiment 17

[0191] The difference between this embodiment and embodiment 1 is that in the reaction solution formula, the blocking agent is replaced by 30 μl of THBR-2 and 30 μl of A1101.

[0192] Embodiment 18

[0193] This embodiment provides a method for determining p2PSA based on latex-enhanced immunoturbidimetry, comprising the following steps:

[0194] Testing instrument: Hitachi 7180 fully automatic biochemical analyzer;

[0195] Temperature: 37℃; Colorimetric cup light path: 1cm;

[0196] Analysis method: two-point endpoint method (take the absorbance at the 16th point and the 34th point), main wavelength: 570nm;

[0197] Reagent volume: S: R1: R2 = 15uL: 180uL: 60uL (where S is the sample, R1 is the reaction solution, and R2 is the latex antibody reagent);

[0198] Calibrator formula: 20 mM PB (phosphate buffer); 0.9 wt% NaCl; 0.1 v / v% P300; human p2PSA antigen concentrations are 0, 506.3, 1012.5, 2025, 4050, 8100 pg / mL;

[0199] The use steps of the kit of the present invention are to mix the reaction solution R1 and the sample (or purified water, or bridge standard), incubate at 37°C for 5 minutes, then add the latex antibody reagent R2, mix, incubate at 37°C for 30 seconds, read the absorbance A1 of each tube, incubate for another 4.5 minutes, and read the absorbance A2 of each tube, as shown in the following table:

[0200] Table 6

[0201]

[0202] The calibration method is multi-point nonlinear Spline. Using the multi-point calibration mode, purified water is used as the zero point to calibrate the calibration product and establish the working curve.

[0203] Calculation method: Fit a calibration curve based on the concentration of the calibrator to the corresponding ΔA. Taking the kit of Example 1 as an example, the calibration curve is as follows: Figure 1 As shown, the sample concentration is obtained through the calibration curve, and the correlation between the measured value and the theoretical concentration is as follows Figure 2 shown.

[0204] Experimental Example Kit New Function Evaluation

[0205] 1) Effect of microspheres of different particle sizes on signal value

[0206] Comparing Example 1 and Comparative Examples 1-4, the calibration solution was taken to implement the fitting standard curve according to Example 18. It was found that Example 1 (mixed microspheres of large and small particle sizes) had higher sensitivity and wider linearity than single 405nm microspheres (Comparative Example 1), 71nm microspheres (Comparative Example 2), 272nm (Comparative Example 3), and 83nm (Comparative Example 4). See the following table and Figure 3. Although the single large-particle microsphere 405nm has high sensitivity, the linearity is poor, and the signal value at 4050pg / mL is indistinguishable from the signal value at 8100pg / mL. Although the single small-particle microsphere 71nm has wide linearity, the sensitivity is poor, and the signal value at 506.3pg / mL is too weak. Mixing large and small-particle microspheres ensures both sensitivity and linearity. In summary, Example 1 (mixing large and small-particle microspheres) is the optimal condition.

[0207] Table 7. Comparison of signal values ​​of microspheres with large and small particle sizes

[0208]

[0209] 2) The effect of mixing different monoclonal antibodies on signal value

[0210] Comparing Example 1 and Comparative Examples 5-7 of the present invention, the calibration solution was taken to implement the fitting standard curve according to Example 18. It was found that Example 1 (p2PSA-1: p2PSA-2: p2PSA-3 = 1: 1: 1) was more sensitive and had a wider linearity than the paired monoclonal antibodies p2PSA-1: p2PSA-2 = 1: 1 (Comparative Example 5), p2PSA-1: p2PSA-3 = 1: 1 (Comparative Example 6), and p2PSA-2: p2PSA-3 = 1: 1 (Comparative Example 7). See the following table and Figure 4 .

[0211] Table 8. Comparison of mixed signal values ​​of monoclonal antibodies from different strains

[0212]

[0213] 3) The influence of the mixing ratio of large and small particle size microspheres on the signal value

[0214] Comparing the examples 1 and 2-5 of the present invention, the calibration solution was taken to implement the fitting standard curve according to example 18. It was found that the linearity of example 1 (mixing ratio of large and small particle size microspheres was 1:1) was the best, followed by example 2 (mixing ratio of large and small particle size microspheres was 2:1) and example 3 (mixing ratio of large and small particle size microspheres was 1:2), and the linearity of example 4 (mixing ratio of large and small particle size microspheres was 3:1) and example 5 (mixing ratio of large and small particle size microspheres was 1:3) was the worst. See the following table and Figure 5 In summary, the mixing ratio of large and small particle size microspheres ranges from 1:2 to 2:1, and the optimal ratio is 1:1. Beyond this range, the linearity will deteriorate.

[0215] Table 9 Comparison of mixing ratios of large and small particle size microspheres

[0216]

[0217] 4) Effects of different sensitizers on signal values

[0218] Comparing the embodiment 1 and the embodiments 6-7 of the present invention, the calibration solution was taken to implement the fitting standard curve according to the embodiment 18. It was found that the linearity of the embodiment 1 (the turbidity enhancer is Biolipidure 103) and the embodiment 7 (the sensitizer is Biolipidure 405) was good, and the signal values ​​were close. The signal value intensity of the embodiment 6 (the sensitizer is PEG6000) was weaker than that of the embodiment 1 (the turbidity enhancer is Biolipidure 103) and the embodiment 7 (the sensitizer is Biolipidure 405). See the following table and Figure 6 In summary, Biolipidure series of turbidity enhancers have better effects.

[0219] Table 10. Comparison of different sensitizers

[0220]

[0221] 5) Blank limit

[0222] The blank sample (physiological saline containing 5% bovine serum) was measured 20 times using the kit of the present invention, and the blank limit was obtained by the mean value of the blank + 2SD according to Example 18, as shown in Table 11. From the results, the blank limit of Example 1 was 1.05, which was significantly better than other examples and comparative examples.

[0223] Table 11 Blank limit determination results of the kit of the present invention

[0224]

[0225]

[0226] 6) Precision

[0227] The p2PSA sample was tested according to Example 18, and the test was repeated 10 times. The mean value (X) and standard deviation (s) of the measured values ​​were calculated, and the coefficient of variation (CV) of the measured results was calculated using the formula: The results are as follows:

[0228] Table 12 Precision determination results of the kit of the present invention

[0229] Precision Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 1 510.2 522.4 503.5 552.3 561.2 2 513.8 501.3 543.2 501.3 511.3 3 511.1 531.5 551.3 515.3 515.4 4 509.8 509.8 508.1 508.9 509.3 5 510.1 512.3 514.2 518.5 512.3 6 511.2 511.2 513.2 509.3 503.5 7 511.1 509.5 507.5 508.4 511.5 8 509.1 509.1 511.3 543.5 501.2 9 510.2 513.2 510.5 512.4 510.3 10 511.2 541.3 511.5 506.8 513.2 Mean 510.78 516.16 517.43 517.67 514.92 SD 1.27 12.06 16.12 16.73 16.83 CV 0.25% 2.34% 3.12% 3.23% 3.27%

[0230] It can be seen from the test results that the CV value of the precision of Example 1 is the lowest, which is the best and is significantly better than other comparative examples.

[0231] 7) Linear

[0232] The high concentration sample close to the upper limit of the linear interval is diluted with the low concentration sample close to the lower limit of the linear interval, and mixed into at least 7 dilution concentrations (xi). The above samples are tested respectively with the kit, and each dilution concentration is tested 3 times according to Example 18, and the mean value (yi) of the test results of each dilution concentration is calculated respectively. The linear regression equation is calculated with the dilution concentration (xi) as the independent variable and the mean value (yi) of the test results as the dependent variable: represents the mean of x, Represents the mean of y. Calculate the correlation coefficient r of linear regression, the calculation formula is Absolute deviation = mean - estimated value. Relative deviation = (mean - estimated value) / estimated value. Plot a linear equation with the theoretical value and the mean, and use EXCEL to plot all theoretical values ​​as the X axis and all mean values ​​as the Y axis to obtain the linear equation Y = kX + b, where k is the slope and b is the intercept. Then substitute the specific theoretical value as the X value into the linear equation to calculate the corresponding estimated value. The results are as follows:

[0233] Table 13 Example 1 Kit Linearity Determination Results

[0234]

[0235] Table 14 Example 3 Kit Linearity Determination Results

[0236]

[0237] Table 15 Example 4 Kit Linearity Determination Results

[0238]

[0239]

[0240] Table 16 Example 5 Kit Linearity Determination Results

[0241]

[0242] Table 17 Example 6 Kit Linearity Determination Results

[0243]

[0244]

[0245] Table 18 Example 9 Kit Linearity Determination Results

[0246]

[0247] Table 19 Example 10 Kit Linearity Determination Results

[0248]

[0249]

[0250] Table 20 Example 11 Kit Linearity Determination Results

[0251]

[0252] It can be seen from the test results that the linear relative deviation of Example 1 is within 10%, and the linearity is obviously better than that of other examples.

[0253] 8) Accuracy

[0254] Clinical comparison experiment: The kit of the present invention was compared with the prostate specific antigen isoform determination kit (control) of Beckman Coulter (USA) Inc., and 40 clinical serum samples were tested to verify the correlation between the two. The implementation method was implemented according to Example 18, and the test results are shown in Table 20. The comparison results of the test results of the kit of Example 1 and the test results of the Beckman Coulter kit are shown in Table 21. Figure 7 shown.

[0255] Table 18 Comparison of clinical test results of the kit of the present invention (unit: pg / mL)

[0256]

[0257]

[0258] It can be seen from the test results that the clinical comparison correlation R between Example 1 and the prostate specific antigen isoform determination kit of Beckman Coulter (USA) Inc. is 0.9982, which is significantly better than other examples.

[0259] 9) Anti-interference

[0260] Anti-interference experiment: The kits in the following examples were used respectively, and the implementation method was implemented according to Example 18. The samples were tested, and blank water (as a reference), fat emulsion, bilirubin, RF, and hemoglobin were added to the samples respectively. The relative deviation calculation formula was (mean-water) / water. The combined use of three blockers in Example 1 (THBR-1, THBR-2, A1101) of the present invention had the best effect and the smallest relative deviation, which was better than other Examples 12 (THBR-1), Example 13 (THBR-2), Example 14 (A1101), Example 15 (THBR-1, THBR-2), Example 16 (THBR-1, A1101), and Example 17 (THBR-2, A1101).

[0261] Table 19

[0262]

[0263]

[0264]

[0265]

[0266] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A kit for determining p2PSA based on latex-enhanced immunoturbidimetry, characterized in that: The kit comprises: a latex antibody reagent; The latex antibody reagent includes a mixture of a first latex antibody reagent and a second latex antibody reagent; the first latex antibody reagent is formed by coupling a polyclonal antibody of p2PSA with large-particle latex microspheres; the particle size range of the large-particle latex microspheres is 172 to 405 nm; the second latex antibody reagent is formed by coupling a monoclonal antibody of p2PSA with small-particle latex microspheres; the particle size range of the small-particle latex microspheres is 71 to 121 nm; the monoclonal antibody of p2PSA includes 3 different monoclonal antibodies of p2PSA.

2. The kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to claim 1, characterized in that: The polyclonal antibody to p2PSA is p2PSA-pAb; And / or, the monoclonal antibody against p2PSA includes p2PSA-1, p2PSA-2 and p2PSA-3 monoclonal antibodies; the p2PSA-1 monoclonal antibody is p2PSA-mAb-1; the p2PSA-2 monoclonal antibody is p2PSA-mAb-2; and the p2PSA-3 monoclonal antibody is p2PSA-mAb-3.

3. The kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to claim 2, characterized in that: The particle size of the large-particle latex microspheres is 405nm, 218nm, 192nm or 172nm, preferably 405nm; And / or, the particle size of the small-size latex microspheres is 71 nm, 89 nm, 100 nm, 108 nm or 121 nm, preferably 71 nm; And / or, the volume ratio of the polyclonal antibody of p2PSA to the large-particle latex microspheres is 2 to 5:1, preferably 2:1; the concentration of the polyclonal antibody of p2PSA is 2 mg / L to 20 mg / L; the concentration of the large-particle latex microspheres is 0.5% w / v to 1% w / v; And / or, the volume ratio of the p2PSA monoclonal antibody to the small-particle latex microspheres is 2 to 5:1, preferably 2:1; the concentration of the p2PSA monoclonal antibody is 2 mg / L to 20 mg / L; the concentration of the small-particle latex microspheres is 0.5% w / v to 1% w / v; and / or, the mass ratio of p2PSA-1, p2PSA-2 and p2PSA-3 monoclonal antibodies is 1:1:9 to 9:1:1; preferably 1:1:1; And / or, the volume ratio of the first latex antibody reagent to the second latex antibody reagent is 1:3 to 3:1, preferably 1:2 to 2:1; preferably, 1:1; And / or, the concentration of the polyclonal antibody of p2PSA and the large-size latex microsphere conjugate in the first latex antibody reagent is 0.1-0.5w / v%, preferably 0.3w / v%; And / or, the concentration of the conjugate of p2PSA monoclonal antibody and small-particle latex microspheres in the second latex antibody reagent is 0.05-0.3w / v%, preferably 0.1w / v%.

4. The kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to any one of claims 1 to 3, characterized in that: Also includes a reaction solution; the reaction solution includes at least one of a buffer, an inorganic salt, a sensitizer, a surfactant, a blocking agent, and a preservative; The buffer comprises any one of N(2-acetylamino)-2-iminodiacetic acid buffer, piperidine-N,N-bis(2-ethanesulfonic acid) buffer, 3-[N,N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer; And / or, the inorganic salt includes at least one of sodium molybdate, ammonium molybdate, sodium bisulfate or ammonium bisulfate; And / or, the sensitizer includes at least one of Biolipidure 103, Biolipidure 405, and PEG 6000; preferably Biolipidure 103 and / or Biolipidure 405; And / or, the preservative is at least one of sodium azide, gentamicin, and isothiazolinone; And / or, the surfactant is at least one of polyoxyethylene fatty alcohol ether, fatty acid glyceride, sucrose fatty acid ester, fatty acid sorbitan, and polysorbate; And / or, the blocking agent is at least one of THBR-1, THBR-2, and A1101; preferably, THBR-1, THBR-2, and A1101, with a volume ratio of 0.5-1.5:0.5-1.5:0.5-1.5, more preferably 1:1:1; Optionally, the reaction solution includes: 13-18.2 g / L buffer, 8.5-20 g / L inorganic salt, 20-35 g / L sensitizer, 0.1-0.2 v / v% surfactant, 0.002-0.006 v / v% blocker, 0.5-1.5 g / L preservative; pH is 7.2±0.05-8.2±0.

05.

5. The kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to any one of claims 1 to 4, characterized in that: Also included is a calibrator; the calibrator contains human p2PSA antigen; Optionally, the calibrator comprises 13 to 18.2 g / L of buffer, 0.5 to 1 g / L of protective agent, and 13 to 18.2 g / L of preservative; Optionally, the buffer comprises any one of a phosphate buffer, an N(2-acetylamino)-2-iminodiacetic acid buffer, a piperidine-N,N-bis(2-ethanesulfonic acid) buffer, a 3-[N,N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and a 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer; Optionally, the protective agent is at least one of bovine serum albumin, casein, gelatin or NaCl; Optionally, the preservative is at least one of sodium azide, gentamicin, and isothiazolinone.

6. A method for preparing a kit for determining p2PSA based on latex-enhanced immunoturbidimetry as claimed in any one of claims 1 to 5, characterized in that: The steps include: The large-size latex microspheres and the small-size latex microspheres are activated by EDC and N-hydroxysulfosuccinimide (sulfo-NHS) respectively for later use; The activated large-size latex microspheres are coupled with the polyclonal antibody of p2PSA, blocked, centrifuged to remove the supernatant, and resuspended to obtain the first latex antibody reagent; The activated small-size latex microspheres are coupled with the p2PSA monoclonal antibody, blocked, centrifuged to remove the supernatant, and resuspended to obtain a second latex antibody reagent; The first latex antibody reagent and the second latex antibody reagent are mixed in proportion to obtain a latex antibody reagent.

7. The method for preparing a kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to claim 6, characterized in that: Prior to coupling, the large-size latex microspheres are washed, centrifuged, and redissolved; and / or, before coupling, the small-size latex microspheres are washed, centrifuged, and redissolved; And / or, the volume ratio of carbodiimide and N-hydroxysulfosuccinimide added is 3-5:6-10, preferably 1:2, the concentration of carbodiimide is 10-30 mg / ml, and the concentration of sulfosuccinimide is 20-30 mg / mL; And / or, the blocking solution used in the blocking step includes at least one of DB1130, CE510, and CE210; And / or, the resuspension step uses a preservation solution for resuspension, and the preservation solution includes a buffer, a stabilizer, a surfactant and a preservative; wherein the buffer includes any one of piperidine-N, N-bis(2-ethanesulfonic acid) buffer, 3-[N, N-bis(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer; the stabilizer includes at least one of gelatin or casein; the surfactant is at least one of polyoxyethylene fatty alcohol ether, fatty acid glyceride, sucrose fatty acid ester, fatty acid sorbitan, and polysorbate; the preservative is at least one of sodium azide, gentamicin, and isothiazolinones.

8. Use of a kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to any one of claims 1 to 5 in preparing a product for determining p2PSA.

9. A method for determining p2PSA based on latex-enhanced immunoturbidimetry, characterized in that: The sample to be tested is used to carry out immune reaction using the kit for determining p2PSA based on latex-enhanced immunoturbidimetry according to any one of claims 1 to 5, and the turbidity of the obtained reaction product is detected.

10. The method for determining p2PSA based on latex-enhanced immunoturbidimetry according to claim 9, characterized in that: include: The sample to be tested and the calibrator are mixed with the reaction solution respectively, incubated, and then the latex antibody reagent is added, and then the absorbance of the sample to be tested and the calibrator is measured respectively; a standard curve is drawn according to the content of the calibrator and the measured absorbance, and the content of p2PSA in the sample to be tested is calculated according to the standard curve; Optionally, the volume ratio of the sample to be tested, the reaction solution and the latex antibody reagent is 10-20:90-270:30-90, preferably 15:180:60.

Citation Information

Patent Citations

  • Kit for determining Lp-PLA2 based on latex particle-enhanced turbidimetric immunoassay and preparation method of kit

    CN108008130A

  • Kit for determining D-dimer based on latex enhanced immunoturbidimetry and preparation method of kit

    CN112485444A

  • NAG latex enhanced immunoturbidimetry kit and detection method

    CN117805378A

  • Reagent kit used for detecting lipoprotein-associated phospholipase a2, and preparation method and application for reagent kit

    WO2016127319A1

  • Method for determination of members of the s100 family of calcium binding proteins by immunoturbidimetry

    WO2018206737A1